MADISON, N.J., May 15 /PRNewswire-FirstCall/ -- Wyeth announced today that the jury in the case of Merle and Steven Simon v. Wyeth, in the Philadelphia Court of Common Pleas, found in favor of Wyeth.
The trial began on April 17, 2007, before The Honorable Nitza I. Quinones Alejandro. James Morris of the Texas firm Brent Coon & Associates and James J. Binns of the Pennsylvania firm James J. Binns, P.C., represented the plaintiffs.
"The evidence presented demonstrated that Wyeth acted responsibly by performing and supporting studies that examined the known and potential benefits and risks of hormone therapy and by keeping the U.S. Food and Drug Administration, physicians and patients informed of those benefits and risks," says Heidi K. Hubbard, a partner with Williams & Connolly LLP, a firm representing Wyeth in the case. "We believe the jury's decision as to Wyeth was consistent with the evidence presented and the body of scientific knowledge concerning hormone therapy."
Premarin(R) (conjugated estrogens tablets USP) and Prempro(TM) (conjugated estrogens/medroxyprogesterone acetate tablets) are approved by the U.S. Food and Drug Administration as safe and effective when used as indicated.
About Wyeth
Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include risks associated with the inherent uncertainty of the timing and success of product research, development and commercialization (including with respect to our pipeline products), drug pricing and payment for our products by government and third-party payors, manufacturing, data generated on the safety and efficacy of our products, economic conditions including interest and currency exchange rate fluctuations, changes in generally accepted accounting principles, the impact of competitive or generic products, trade buying patterns, global business operations, product liability and other types of litigation, the impact of legislation and regulatory compliance, intellectual property rights, strategic relationships with third parties, environmental liabilities, and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, RISK FACTORS." We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
